Incretin Atlas › Trials › Phase 3 add-on to metformin (Lancet RH-WP 2024;51:101197)
Phase 3 add-on to metformin (Lancet RH-WP 2024;51:101197)
PB-119 · t2d
Design
- Molecule(s)
- PB-119
- Population
- t2d
- Phase
- 3
- Participants
- 310
- Duration
- 24 weeks
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 150 μg QW | t2d china | 24 | 310 | — | — | −1.2 vs −0.7 | — | 7.4 vs 7.7 | 4.2 vs 0.3 | 4.8 vs 0.3 | 2.9 vs 3.9 | — | press release |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- 150 μg QW: Reported 1.9 % for Table 3 row is "TRAE leading to early withdrawal" (treatment-related AEs) 6/310 vs 1/310 (0.3%); text calls the same numbers "due to TEAEs" — inconsistent (not shown on the axis).
Verbatim quotes from the source (5)
- 150 μg QW · hba1c · publication
was −1.25% (95% confidence interval (CI), −1.35 to −1.16) in the visepegenatide group and −0.68% (95% CI, −0.78 to −0.59) in the placebo group.
- 150 μg QW · disc_any · Results, first paragraph
During the 24-week double-blind period, 287 (92.6%) participants in the visepegenatide group and 286 (92.2%) participants in the placebo group completed the treatment and entered the extension phase.
- 150 μg QW · nausea · Table 3, double-blind columns (Visepegenatide N=310, Placebo
Nausea 13 (4.2) 31 1 (0.3)
- 150 μg QW · sae · Table 3, double-blind columns
Serious adverse events (SAEs) 9 (2.9) 10 12 (3.9)
- 150 μg QW · vomiting · Table 3, double-blind columns
Vomiting 15 (4.8) 30 1 (0.3)
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: Phase 3 add-on to metformin (Lancet RH-WP 2024;51:101197). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/phase-3-add-on-to-metformin/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.